Newswire (Published: Monday, February 20, 2017, Received: Thursday, February 16, 2017, 11:06:05 AM CST)

Word Count: 392

By a News Reporter-Staff News Editor at Clinical Trials Week -- New research on Oncology - Prostate Cancer is the subject of a report. According to news reporting out of Trento, Italy, by NewsRx editors, research stated, "Prostate cancer is the most common cancer in men, with an incidence that is expected to increase in the coming years. Prostate cancer is usually diagnosed in men >65 years of age, thus the concurrent presence of cardiovascular diseases might influence the treatment, owing to the increased risk of cardiovascular mortality."

Our news journalists obtained a quote from the research from Santa Chiara Hospital, "The introduction of new drugs, such as abiraterone and enzalutamide for the management of metastatic disease has created further interest in treatment-related cardiovascular toxicities, although limited data from trials specifically designed to identify cardiovascular toxicities of these agents are currently available. The only available data are derived from published phase II-III study reports, expanded access or compassionate use programmes and meta-analyses of the effects of systemic therapies that are already approved for use in clinical practice or are in the early phases of development. These data are conflicting, although they seem to suggest that certain drugs are associated with an increased risk of cardiovascular adverse events. Clinical trial methodology could be improved by the enrolment of greater numbers of patients >65 years of age, and the use of comprehensive cardiological evaluations."

According to the news editors, the research concluded: "Moreover, closer collaboration between oncologists and cardiologists is essential for the identification and/or management of cardiovascular adverse events in patients with prostate cancer."

For more information on this research see: Cardiovascular toxicities of systemic treatments of prostate cancer. Nature Reviews Urology, 2017;():. (Nature Publishing Group - www.nature.com/; Nature Reviews Urology - www.nature.com/nrurol/)

Our news journalists report that additional information may be obtained by contacting A. Veccia, Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d'Oro 38100Trento, Italy. Additional authors for this research include F. Maines, S. Kinspergher, E. Galligioni and O. Caffo (see also Oncology - Prostate Cancer).

Keywords for this news article include: Italy, Trento, Europe, Oncology, Cardiology, Article Review, Cardiovascular, Prostate Cancer, Prostatic Neoplasms, Risk and Prevention.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Industries

Healthcare
      Healthcare Facilities
            Hospitals

Places

Southern Europe
Italy
Europe
Trento

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Medical Specialties and Practices
            Cardiology
            Urology
      Treatments and Therapies
            Medicinal Drugs
                  Cardiovascular Drugs